Stay updated with breaking news from Biosimilar drugs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Mauro Orru Sandoz Group said its U.S. subsidiaries would pay $265 million to settle a generic pharmaceuticals pricing antitrust litigation. The maker of. ....
This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond. ....
Biosimilars have driven down the costs of originator biologics, but it isn't clear whether those savings are being passed on to patients or increasing access to the drugs. ....